ArticleGeroScience2026
Association of biological age acceleration with muscle aging phenotype in young and middle-aged adults: a prospective cohort study.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Loss of muscle mass and quality (myopenia and myosteatosis) are hallmarks of aging and predictors of disability, yet their relationship with biological aging in younger adults is unclear. This prospective cohort study included 165,015 adults (mean age 39.9) who underwent low-dose chest computed tomography (CT) between 2010 and 2020. A longitudinal subset of 61,669 participants had repeated scans (median follow-up 4.1 years). We adopted blood-based Phenotypic Age acceleration (PhenoAgeAccel) and chest radiograph-based biological age acceleration (CXR-AgeAccel). Myopenia and myosteatosis were defined as muscle area and density values more than two standard deviations below young sex-specific reference means. Multivariable multinomial logistic and Cox proportional hazard models estimated associations between biological age acceleration and prevalent or incident muscle abnormalities, adjusting for sociodemographic, lifestyle, and clinical factors. PhenoAgeAccel was associated with higher odds of myopenia (OR 1.16, 95% CI 1.08-1.25), myosteatosis (OR 1.24, 95% CI 1.18-1.29), and combined myopenia-myosteatosis (OR 1.51, 95% CI 1.41-1.63). In longitudinal analyses, PhenoAgeAccel was associated with increased risk of incident myopenia (HR 1.21, 95% CI 1.08-1.35), myosteatosis (HR 1.18, 95% CI 1.09-1.28), and the combined myopenia-myosteatosis (HR 1.29, 95% CI 1.08-1.55). Associations were consistent, though attenuated, with CXR-AgeAccel (OR 1.34, 95% CI 1.20-1.50; HR 1.18, 95% CI 0.96-1.45). Associations persisted among participants < 40 years. Accelerated biological aging measured from routine blood and imaging data was associated with early deterioration in muscle mass and quality. Biological age may represent a practical marker for identifying individuals at risk of early musculoskeletal decline.
Indexed as
Identifiers
42449042What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.